BACKGROUND: Hepatocyte growth factor activator inhibitor type-1 (HAI-1) inhibits hepatocyte growth factor activator and matriptase.
In the present study it was investigated whether the expression of HAI-1 is associated with the progression of prostate cancer.
PATIENTS AND METHODS: The expression of HAI-1 was evaluated by immunohistochemistry (IHC) of samples from 51 patients with negative prostate biopsies and 75 patients with untreated prostate cancer. Furthermore, the expression of HAI-1 was evaluated in 24 patients with castration-resistant prostate cancer (CRPC), and the relationship between HAI-1 expression and the prostate-specific antigen (PSA) progression-free rate was investigated.
RESULTS: Expression of HAI-1 by IHC in patients with prostate cancer was significantly higher than in those with negative prostate biopsy. CRPC exhibited significantly lower HAI-1 expression than untreated metastatic prostate cancer. The PSA progression-free rate was worse in patients without HAI-1 expression than in those with positive HAI-1 expression.
CONCLUSION: It is suggested that HAI-1 may play an important role in the pathogenesis of CRPC.
Written by:
Yasuda K, Komiya A, Watanabe A, Morii A, Oya T, Nagakawa O, Fujiuchi Y, Fuse H. Are you the author?
Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Reference: Anticancer Res. 2013 Feb;33(2):575-81.
PubMed Abstract
PMID: 23393351
UroToday.com Investigative Urology Section
